

# UCLA

## UCLA Previously Published Works

### Title

Psychological interventions for bipolar disorder in low- and middle-income countries: systematic review

### Permalink

<https://escholarship.org/uc/item/5w87v4wr>

### Journal

BJPsych Open, 4(5)

### ISSN

2056-4724

### Authors

Demissie, Mekdes

Hanlon, Charlotte

Birhane, Rahel

et al.

### Publication Date

2018-09-01

### DOI

10.1192/bjo.2018.46

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike License, available at

<https://creativecommons.org/licenses/by-nc-sa/4.0/>

Peer reviewed

## Review

# Psychological interventions for bipolar disorder in low- and middle-income countries: systematic review

Mekdes Demissie, Charlotte Hanlon, Rahel Birhane, Lauren Ng, Girmay Medhin and Abebaw Fekadu

## Background

Adjunctive psychological interventions for bipolar disorder have demonstrated better efficacy in preventing or delaying relapse and improving outcomes compared with pharmacotherapy alone.

## Aims

To evaluate the efficacy of psychological interventions for bipolar disorder in low- and middle-income countries.

## Method

A systematic review was conducted using PubMed, PsycINFO, Medline, EMBASE, Cochrane database for systematic review, Cochrane central register of controlled trials, Latin America and Caribbean Center on Health Science Literature and African Journals Online databases with no restriction of language or year of publication. Methodological heterogeneity of studies precluded meta-analysis.

## Results

A total of 18 adjunctive studies were identified: psychoeducation ( $n = 14$ ), family intervention ( $n = 1$ ), group cognitive-behavioural therapy (CBT) ( $n = 2$ ) and group mindfulness-based cognitive therapy (MBCT) ( $n = 1$ ). In total, 16 of the 18 studies were from upper-middle-income countries and none from low-income countries. All used mental health specialists or experienced therapists to deliver the intervention. Most of the studies have moderately high risk of bias. Psychoeducation improved treatment adherence, knowledge of and attitudes towards bipolar disorder and quality of life, and led to decreased relapse rates and hospital admissions. Family psychoeducation prevented

relapse, decreased hospital admissions and improved medication adherence. CBT reduced both depressive and manic symptoms. MBCT reduced emotional dysregulation.

## Conclusions

Adjunctive psychological interventions alongside pharmacotherapy appear to improve the clinical outcome and quality of life of people with bipolar disorder in middle-income countries. Further studies are required to investigate contextual adaptation and the role of non-specialists in the provision of psychological interventions to ensure scalability and the efficacy of these interventions in low-income country settings.

## Declaration of interest

None.

## Keywords

Psychosocial interventions; bipolar affective disorders; low- and middle-income countries.

## Copyright and usage

© The Royal College of Psychiatrists 2018. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (<http://creativecommons.org/licenses/by-nc-sa/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is included and the original work is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use.

Bipolar disorder is a severe mental illness characterised by recurrent depressive and manic episodes and associated with high levels of disability and premature mortality.<sup>1–3</sup> Although there are limited data from low- and middle-income countries (LMICs), the burden of bipolar disorder may be even higher in these settings because of the high treatment gap.<sup>1</sup> As few as 10% of people with bipolar disorder receive care in some LMICs.<sup>4,5</sup> Even those who receive care may have limited access to evidence-based interventions, including mood stabilisers and psychosocial interventions.<sup>5,6</sup> In a cohort study of 312 community-ascertained people with bipolar disorder in Ethiopia, over 60% relapsed and only 5% remained continuously in remission over 2.5 years of follow-up,<sup>5</sup> which appears much lower than what has been reported in high-income countries.<sup>7</sup> Patients in low-income countries also appear to have substantially increased rates of mortality with nearly three decades of life lost because of premature death.<sup>2</sup>

Mood stabilisers, such as lithium and sodium valproate, and atypical antipsychotics such as olanzapine, quetiapine and risperidone are the recommended evidence-based treatments for bipolar disorder.<sup>8</sup> However, these medications are not widely available in many LMICs.<sup>4,9</sup> As a result, people with bipolar disorder in LMICs are often treated with first-generation antipsychotics during the maintenance phase.<sup>5,6</sup> First-generation antipsychotic

medications are recommended in the latest version of the intervention guide of the Mental Health Gap Action Programme (mhGAP) in the absence of other options.<sup>10</sup> However, they have extrapyramidal side-effects, especially when taken in high doses for an extended period of time<sup>11</sup> and have poor evidence of efficacy as a maintenance treatment. Psychological treatments may play a crucial role in improving the outcome of bipolar disorder in LMICs where first-line treatments are not available for the majority of the population.

There is evidence from high-income countries that complementing pharmacotherapy with psychoeducation, family therapy or cognitive-behavioural therapy (CBT) for people with bipolar disorder is more effective at preventing relapse, improving medication adherence and overall disease outcome than pharmacotherapy alone.<sup>12–14</sup> The mhGAP intervention guideline recommends psychological intervention, especially psychoeducation to be delivered routinely for individuals with bipolar disorders.<sup>15</sup> However, to date there has been no published synthesis of the evidence on the efficacy of adjunctive psychological interventions for bipolar disorder in LMIC settings. In this systematic review we aimed to synthesise the evidence base for the efficacy of adjunctive psychological interventions in improving clinical and functional outcomes in people with bipolar disorder in LMICs.

## Method

### Scope of review

We reviewed studies that aimed to examine the efficacy of any psychological intervention in improving clinical and functional outcomes, including prevention of relapse or recurrence and hospital admissions; treatment adherence, biological rhythms, quality of life (QoL) and knowledge and attitude about bipolar disorder among people with bipolar disorder.

### Search strategies

We searched Medline, PsycINFO, EMBASE, PubMed, Cochrane database for systematic review, Cochrane central register of controlled trials, Latin America and Caribbean Center on Health Science Literature and African Journal of Online databases since the inception of the respective databases until the second week of May 2017 with no language restriction. The following terms were used to identify psychological interventions: 'Psychosocial intervention' OR 'Psychological intervention' OR 'Psychosocial therapy' OR 'Cognitive behavioral therapy' OR 'Cognitive Therapy' OR 'Behavior Therapy' OR 'Family focused intervention' OR 'Family intervention' OR 'Family therapy' OR Psychoeducation OR 'Interpersonal and social rhythm therapy' OR 'Social rhythm therapy' OR 'Interpersonal therapy' OR 'Mindfulness based cognitive therapy' OR Psychotherapy OR 'Expressed emotion' OR 'Individual therapy' OR 'Group therapy'. The search terms used for bipolar disorder were: 'Bipolar disorder' OR 'Bipolar and related disorders' OR Bipolar OR Mania OR 'Major affective disorder'. We used the World Bank definition and list of countries to identify LMICs. The search terms for intervention, bipolar disorder and LMICs were combined with the Boolean term 'AND'.

### Outcomes of interest

The main measures of efficacy of psychological interventions included: number of relapses or recurrence, severity of mood symptoms, treatment adherence, QoL, functional status, number of hospital admissions, knowledge and attitudes about bipolar disorder, and stigma and biological rhythms. The review protocol was registered in the PROSPERO database (CRD42017054572).<sup>16</sup>

### Inclusion criteria

Eligible articles were assessed against the following inclusion criteria:

- age: all ages were included;
- diagnosis: bipolar disorder I or II in any phase of the illness (depressive/manic/mixed episode or in remission);
- study setting: conducted in a LMIC according to the World Bank classification at the time of the study;<sup>17</sup>
- type of study: (i) randomised controlled studies (RCT), or (ii) controlled before-and-after study;
- comparison groups: usual care, waiting list control or an active adjunctive psychological intervention;
- type of intervention: any psychological intervention delivered either face to face (individual or group format) or online.

### Data extraction

Studies were first screened based on their titles and abstracts, with the full texts obtained for those fulfilling the inclusion criteria. Two researchers (M.D. and R.B.) screened and extracted data independently using a customised data extraction form, which was piloted before the main data extraction. Any discrepancies were reconciled

through discussions. Excluded articles and reasons for exclusion were documented.

### Quality assessment

The consolidated standards of reporting studies (CONSORT)<sup>18</sup> and the Cochrane assessment of risk of bias<sup>19</sup> were used to assess the quality of the studies. The CONSORT checklist has 25 items on the quality of reporting of each section of the study including funding sources. The Cochrane assessment of risk of bias measures selection bias, performance bias, detection bias, attrition bias and reporting bias. The quality of studies was assessed independently by two researchers (M.D. and R.B.) and any differences were reconciled by a third researcher (A.F.). Assessment of the quality of the included studies was not used to exclude studies, but, to inform interpretation of the findings.

### Method of analysis

Key findings were summarised in the form of figures, tables and text. Although the original plan was to conduct a meta-analysis and generate summary effect sizes of interventions, this was not possible because of the heterogeneity of the included studies in terms of: type of intervention, number of intervention sessions, duration of follow-up, format of intervention delivery and qualifications of the individuals delivering the intervention.

## Results


A total of 7987 articles were identified from the primary search. Of these, 532 were duplicates and were excluded. An additional 7213 were excluded because they were not related to bipolar disorder or to psychological interventions during the title screen and a further 162 during the abstract screen. Of the 80 studies included in full-text review, 62 were excluded because they were not from LMICs or were not related to bipolar disorder. This resulted in a total of 18 intervention studies for final analysis (Fig. 1). Four types of psychological intervention were identified: psychoeducation, family psychoeducation, CBT and mindfulness-based cognitive therapy (MBCT) (Table 1).

### Included studies

All studies were conducted in upper-middle-income countries except two, which was conducted in middle-income countries. There was only one study from Africa (South Africa). All of the 18 studies were published between 2003 and 2017 and were conducted in six countries. Brazil,<sup>20–24</sup> Turkey<sup>25–29</sup> and Iran<sup>30–34</sup> each contributed five studies, and India,<sup>35</sup> South Africa<sup>36</sup> and Pakistan<sup>37</sup> each contributing only one study. Fifteen studies examined psychoeducation (five individual, nine groups, and one family intervention); two studies were of group CBT; and one study was group MBCT. All studies were RCTs, and all but two studies compared adjunctive psychological interventions with treatment as usual. The nature of 'treatment as usual' or the type of medication, was not specified in all these studies. The two studies that used an intervention comparison group, had used an equal number of sessions of relaxation and informal conversation,<sup>22</sup> or non-specific support.<sup>32</sup> The total number of participants in each study ranged from 26<sup>30</sup> to 59.<sup>33</sup> Overall follow-up time after the end of intervention ranged from 0 to 18 months (Table 1).

### Intervention content and intervention provider

Providers of the intervention were specified in 15 of the 18 studies and included mental health specialists or practitioners (BSc



**Fig. 1** PRISMA flow diagram of the study selection process.

PSI, Psychological intervention; LMICs, low- and middle-income countries.

psychiatric nurses,<sup>25–27</sup> MSc psychiatric nurses,<sup>34</sup> clinical psychologists,<sup>23,32,37</sup> MSc research psychology students,<sup>21</sup> undergraduate psychologists<sup>20</sup> psychiatrists or psychiatric residents<sup>22,31,33</sup>) and

therapists or people with some form of clinical experience.<sup>24,29,35</sup> Although the majority of the studies did not indicated how the interventions were developed or adapted, most of the studies

**Table 1** Summary of studies, interventions and patient characteristics for included studies

| Authors   | Baseline, <i>n</i><br>(intervention/control) | Type of treatment<br>intervention/control | Mode of<br>intervention | Sessions,<br><i>n</i> | Duration of<br>intervention (weeks) | Duration of follow-<br>up (months) |
|---|--|---|-------------------------|-----------------------|-------------------------------------|------------------------------------|
| Faria <i>et al</i> 2014 (Brazil) <sup>20</sup>                  | 32/29  | PE/TAU                                    | Individual              | 6                     | 6                                   | Pre–post                           |
| Husain <i>et al</i> 2017<br>(Pakistan) <sup>37</sup>            | 18/16  | PE/TAU                                    | Individual              | 12                    | 12                                  | Pre–post                           |
| Eker & Harkin 2012<br>(Turkey) <sup>29</sup>                    | 36/35  | PE/TAU                                    | Group                   | 6                     | 6                                   | Pre–post                           |
| Cuhadar <i>et al</i> 2014<br>(Turkey) <sup>27</sup>             | 32/31  | PE/TAU                                    | Group                   | 7                     | 7                                   | Pre–post                           |
| Rahmani <i>et al</i> 2016 (Iran) <sup>34</sup>                  | 38/38  | PE/TAU                                    | Group                   | 10                    | 5                                   | Pre–post                           |
| Dogan & Sabanciogullari<br>2003 (Turkey) <sup>28</sup>          | 16/16  | PE/TAU                                    | Individual              | 3                     | 3                                   | 3                                  |
| George <i>et al</i> 2013 (India) <sup>35</sup>                  | 30/30  | PE/TAU                                    | Group                   | 4                     | 16                                  | 3                                  |
| Kurdal <i>et al</i> 2014<br>(Turkey) <sup>26</sup>              | 40/40  | PE/TAU                                    | Group                   | 21                    | 11                                  | 3                                  |
| Faridhosseini <i>et al</i> 2017<br>(Iran) <sup>30</sup>         | 13/13  | PE/TAU                                    | Group                   | 8                     | 4                                   | 6                                  |
| Cardoso <i>et al</i> 2014<br>(Brazil) <sup>21</sup>             | 32/29  | PE/TAU                                    | Group                   | 6                     | 6                                   | 6                                  |
| Bahredar <i>et al</i> 2014<br>(Iran) <sup>32</sup>              | 15/15/15                                     | PE/TAU/placebo                            | Group                   | 9                     | 9                                   | 6                                  |
| de Barros <i>et al</i> 2013<br>(Brazil) <sup>22</sup>           | 32/23  | PE/placebo                                | Group                   | 16                    | 16                                  | 12                                 |
| Gumus <i>et al</i> 2015<br>(Turkey) <sup>25</sup>               | 41/41  | PE/TAU                                    | Individual              | 4                     | 4                                   | 12                                 |
| Javadpour <i>et al</i> 2013<br>(Iran) <sup>31</sup>             | 54/54  | PE/TAU                                    | Individual              | 8                     | 8                                   | 18                                 |
| Bordbar <i>et al</i> 2009 (Iran) <sup>33</sup>                  | 29/30  | FPE/TAU                                   | Group                   | 1                     | 1                                   | 12                                 |
| Costa <i>et al</i> 2012 (Brazil) <sup>23</sup>                  | 27/14  | CBT/TAU                                   | Group                   | 14                    | 14                                  | 6                                  |
| Gomes <i>et al</i> 2011 (Brazil) <sup>24</sup>                  | 23/27  | CBT/TAU                                   | Group                   | 18                    | 22                                  | 12                                 |
| Ives-Deliperi <i>et al</i> 2013<br>(South Africa) <sup>36</sup> | 16/7/10                                      | MBCT/TAU/HC                               | Group                   | 8                     | 8                                   | Pre–post                           |

PE, psychoeducation; TAU, treatment as usual; FPE, family psychoeducation; CBT, cognitive–behavioural therapy; MBCT, mindfulness-based cognitive therapy; HC, Healthy control.

**Table 2** Psychological interventions for prevention of relapse/recurrence

| Authors  | Intervention group | Final analysis, <i>n</i> (intervention/ control) | Outcome measured                                     | Proportion with outcome |               | $\chi^2$ | Z      | P      |
|--|--------------------|--|--|-------------------------|---------------|----------|--------|--------|
|  |                    |  |  | Intervention group      | Control group |          |        |        |
| de Barros <i>et al</i> 2013 (Brazil) <sup>22</sup>   | G-PE v. placebo    | 28/18  | Depressive relapse                                   | –                       | –             | –        | –      | 0.18   |
|  |                    |  | Manic relapse  | –                       | –             | –        | –      | 0.09   |
| Gomes <i>et al</i> 2011 (Brazil) <sup>24</sup>       | G-CBT v. TAU       | 22/25  | Relapse, <i>n</i>                                    | 14/23                   | 14/27         | 0.28     | –      | 0.590  |
|  |                    |  | Time to first relapse, median (range) weeks          | 31 (66)                 | 11.5 (48)     | –        | –2.554 | 0.011  |
| Gumus <i>et al</i> 2015 (Turkey) <sup>25</sup>       | I-PE v. TAU        | 37/41  | Recurrence, <i>n</i>                                 | 7/37                    | 14/41         | 1.583    | –      | 0.21   |
|  |                    |  | Experienced more than one recurrence, <i>n</i>       | 2                       | 8             | 0.36     | –      | 0.221  |
| Faridhosseini <i>et al</i> 2017 (Iran) <sup>30</sup> | G-PE v. TAU        | 12/12  | Recurrence, <i>n</i>                                 | 1/13                    | 9/13          | –        | –      | 0.001  |
|  |                    |  | Patients experienced more than one relapse, <i>n</i> | 0                       | 2             | –        | –      | –      |
| Javadpour <i>et al</i> 2013 (Iran) <sup>31</sup>     | I-PE v. TAU        | 45/41  | Average number of recurrences                        | 0.77                    | 2.02          | –        | –      | <0.001 |
| Bordbar <i>et al</i> 2009 (Iran) <sup>33</sup>       | G-FPE v. TAU       | 29/28  | Total relapse, <i>n</i>                              | 4/29                    | 9/28          | –        | –      | 0.006  |
|  |                    |  | Experienced more than one recurrence, <i>n</i>       | 1                       | 2             | –        | –      | –      |
|  |                    |  | Time to first relapse in months, mean                | 6                       | 4.8           | –        | –      | –      |

G-PE, group psychoeducation; G-CBT, group cognitive-behavioural therapy; TAU, treatment as usual; I-PE, individual psychoeducation; G-FPE, group family psychoeducation.

described the core content of the interventions. The content in most of the interventions was educational: education about bipolar disorder, symptoms of mania, depression, mixed and hypomanic episodes, causes and prognosis of bipolar disorder, treatment adherence and side-effects of medication, early identification of symptoms of relapse, triggering factors, substance use and regular habits and management plans or prevention strategies.

#### Participant recruitment and outcome measures

The study participants were aged at least 18 years in all of the studies. Most of the participants were in remission during recruitment to the study and were recruited from the out-patient setting of a teaching or university hospital or from a public hospital. Most were receiving pharmacotherapy and follow-up from psychiatrists. In the majority of studies the Young Mania Rating Scale was used to measure manic symptom severity either as a categorical scale with an average cut-off of nine<sup>22–25,30,32,34–37</sup> or as a continuous scale.<sup>20,21</sup> Similarly, in the majority of the studies, the Hamilton Rating Scale for Depression was used to measure depressive symptom severity either as a categorical scale with an average cut-off point of eight<sup>22,24,25,30–32,34,35</sup> or as a continuous measure.<sup>20,21</sup> Five studies included people with bipolar I or II disorder, three studies recruited only individuals with bipolar I disorder and two studies recruited only those with bipolar II disorder; the remaining eight studies did not specify the type of bipolar disorder. In 16 studies, the DSM-IV was used as the diagnostic tool, with psychiatrist-confirmed diagnoses in 11 studies. Two studies did not describe who confirmed the diagnosis.<sup>27,35</sup> Details of other outcome measures are provided in supplementary file 1 available at <https://doi.org/10.1192/bjo.2018.46>.

#### Quality of included studies

The overall quality of reporting of the studies was not satisfactory as per the CONSORT checklist. Only three of the studies were registered in a registration database. Although all studies clearly reported the objective of the study. Only 55% of the studies reported how the sample size was determined. Sources of funding and the role of funders were reported in only two-thirds of the studies. The risk of bias assessed with the Cochrane assessment tool was moderately high. Although randomisation was carried out in all the studies, the

method of randomisation was unclear in 40% of studies and allocation concealment was unclear in 80% of studies. Fifteen studies were rated as unclear and three studies had a high risk of detection bias. One-third of the studies were rated as having high attrition bias because of unequal numbers of people dropping out in the randomised groups or different reasons for drop-out or because of attrition greater than 10%. One-third of studies were rated as being at high risk of reporting bias because they did not report the mean and standard deviation of mood severity symptoms, between-group differences for selected outcomes, and number of participants who had a relapsed/recurrence (see supplementary files 2–4).

#### Efficacy of interventions

##### Prevention of relapse/recurrence

Six studies (four psychoeducation, one family psychoeducation and one CBT) examined the impact of the psychological intervention on prevention of relapse or recurrence (Table 2). Psychoeducation was effective in reducing the relapse rate,<sup>25,30,31,33</sup> as well as increasing mean time to first relapse.<sup>33</sup> However, one study showed that psychoeducation was not effective in people who had multiple previous relapses.<sup>22</sup> CBT was ineffective in decreasing the number of relapses but was effective in prolonging the median time to first relapse compared with treatment as usual.<sup>24</sup>

##### Reduction in symptom severity

Nine studies (seven psychoeducation, one CBT and one MBCT) assessed the efficacy of psychological intervention in reducing symptom severity. One study reported change in mood-only symptom severity within each of the randomised groups<sup>28</sup> (Table 3).

Studies reported significant reduction in general psychiatric symptom severity,<sup>28</sup> depressive symptom severity<sup>21,31,37</sup> and manic symptom severity,<sup>20,21,30,31,37</sup> immediately post-intervention and during follow-up. However, in one study where 60% of total participants had more than ten previous bipolar episodes, there was worsening of depressive symptoms in both groups and there was significant change and between-group difference in manic symptoms.<sup>22</sup> CBT was effective in reducing depressive and anxiety symptoms compared with treatment as usual.<sup>23</sup> MBCT was associated with significant improvement in anxiety symptoms, emotional dysregulation and mindfulness, but did not reduce

**Table 3** Psychological intervention for reducing symptom severity

| Authors  | Final analysis, <i>n</i><br>(intervention/control) | Intervention    | Assessment time<br>(month) | Test statistics<br>and <i>P</i>   | Measure of effect  |
|--|--|-----------------|----------------------------|---|--|
| Mood symptom severity<br>Dogan & Sabanciogullari<br>(2003) <sup>28</sup>   | 14/12  | I-PE v. TAU     | 3                          | I-PE: $Z = 2.41$ ;<br>$P < 0.01^a$<br>TAU: $Z = 1.05$ ;<br>$P > 0.05^a$ | –  |
| Depressive symptoms<br>Faria <i>et al</i> (2014) <sup>20</sup>             | 19/26  | I-PE v. TAU     | Post-intervention          | $P = 0.40$  | AMD = $-1.86$ (95% CI $-6.34$ to $2.61$ )                |
| Husain <i>et al</i> (2017) <sup>37</sup>                                   | 16/11  | I-PE v. TAU     | 3                          | $Z = 3.21$ ; $P = 0.001$  | AMD = $-10.3$ (95% CI $-16.8$ to $-4.5$ ), SES = $-1.17$ |
| Javadpour <i>et al</i> (2013) <sup>31</sup>                                | 45/41  | I-PE v. TAU     | 18                         | $P < 0.001$   | –  |
| Faridhosseini <i>et al</i> (2017) <sup>30</sup>                            | 12/12  | G-PE v. TAU     | Post-intervention          | $P = 0.58$  | Mean 1.0 (s.e. = 1.78)                                   |
| Cardoso <i>et al</i> (2014) <sup>21</sup>                                  | 19/26  | G-PE v. TAU     | Post-intervention          | $F = 0.66$ , $P = 0.81$   | –  |
|  |  |                 | 6                          | $F = 0.99$ , $P = 0.324$  | –  |
| de Barros <i>et al</i> (2013) <sup>22</sup>                                | 28/18  | G-PE v. placebo | 12                         | $P = 0.820$   | ES = 0.007   |
| Costa <i>et al</i> (2012) <sup>23</sup>                                    | 25/12  | G-CBT v. TAU    | 6                          | $P < 0.05$  | –  |
| Ives-Deliperi <i>et al</i> (2013) <sup>36</sup>                            | 16/7   | G-MBCT v. TAU   | Post-intervention          | $P > 0.05$  | –  |
| Manic symptoms<br>Faria <i>et al</i> 2014 <sup>20</sup>                    | 19/26  | I-PE v. TAU     | Post-intervention          | $P = 0.06$  | AMD = $-5.93$ (95% CI $-0.28$ to $-12.15$ )              |
| Husain <i>et al</i> 2017 <sup>37</sup>                                     | 16/11  | I-PE v. TAU     | 3                          | $Z = 4.67$ , $P < 0.001$  | AMD = $-6.0$ (95% CI $-8.7$ to $3.7$ ),<br>SES = $-1.18$ |
| Javadpour <i>et al</i> 2013 <sup>31</sup>                                  | 45/41  | I-PE v. TAU     | 18                         | $P < 0.001$   | –  |
| Faridhosseini <i>et al</i> 2017 <sup>30</sup>                              | 12/12  | G-PE v. TAU     | Post-intervention          | $P = 0.04$  | Mean 1.91 (s.e.) 0.88                                    |
| Cardoso <i>et al</i> (2014) <sup>21</sup>                                  | 19/26  | G-PE v. TAU     | Post-intervention          | $F = 2.16$ , $P = 0.15$   | –  |
|  |  |                 | 6                          | $F = 2.94$ , $P = 0.09$   | –  |
| de Barros <i>et al</i> (2012) <sup>22</sup>                                | 28/18  | G-PE v. placebo | 12                         | $P = 0.72$  | ES = 0.02  |
| Costa <i>et al</i> (2012) <sup>23</sup>                                    | 25/12  | G-CBT v. TAU    | 6                          | $P > 0.05$  | –  |
| Anxiety symptoms<br>Ives-Deliperi <i>et al</i> (2013) <sup>36</sup>        | 16/7   | G-MBCT v. TAU   | Post-intervention          | $t = 2.3$ , $P = 0.05$  | –  |
| Costa <i>et al</i> (2012) <sup>23</sup>                                    | 25/12  | G-CBT v. TAU    | 6                          | $P = 0.02$  | $R^2 = 0.9$  |
| Emotional dysregulation<br>Ives-Deliperi <i>et al</i> (2013) <sup>36</sup> | 16/7   | G-MBCT v. TAU   | Post-intervention          | $t = 4.1$ , $P = 0.01$  | –  |

I-PE, individual psychoeducation; TAU, treatment as usual; AMD, adjusted mean difference; SES, standardised effect size; G-PE, group psychoeducation; ES, effect size; G-CBT, group cognitive-behavioural therapy; G-MBCT, group mindfulness-based cognitive therapy;  $R^2$ , squared value of correlation coefficient or the proportion of explained variation.  
a. The comparison was made within arm and the reported result for the treatment group.

depressive symptoms among intervention groups compared with the patients with bipolar disorder on the waiting list.<sup>36</sup>

#### Improvement in biological rhythms

Only one study<sup>20</sup> from Brazil assessed the efficacy of six sessions of complementary psychoeducation in improving biological rhythms (sleep, activity, patterns of habitual daily behaviour (social rhythm) and eating pattern) among patients with bipolar disorder, 80% of whom had more than six previous bipolar episodes. The study reported significant improvement in the control rather than the intervention group (adjusted mean difference  $-10.84$ , 95% CI  $-20.6$  to  $-1.07$ ,  $P = 0.03$ ).<sup>20</sup>

#### Improvement in knowledge, attitude and internalised stigma

Four psychoeducation studies were identified.<sup>27,28,35,37</sup> Three of the four studies assessed the efficacy of psychoeducation in improving knowledge and attitudes about bipolar disorder, and one trial assessed the efficacy of psychoeducation in reducing internalised stigma. Two of the four studies reported within-group difference by comparing post-intervention against baseline scores in each group.<sup>27,28</sup> Generally, the findings showed a positive effect of psychoeducation in improving knowledge and attitudes about bipolar disorder and internalised stigma (see supplementary file 5).

#### Improvement in treatment adherence

A total of nine studies, eight psychoeducation and one family-focused intervention, reported short- and long-term improvements in treatment adherence compared with treatment as usual<sup>28–35,37</sup> (Table 4).

#### Reduction in hospital admissions

A total of five RCTs that assessed the efficacy of individual, group or family psychoeducation in reducing hospital admissions were identified (see supplementary file 6). Generally, the studies showed that fewer people with bipolar disorder were admitted to hospital in the intervention group compared with the control group.<sup>25,30,31,33</sup>

#### Improvement in QoL and functional status

A total of 10 of the 18 studies (9 psychoeducation and 1 CBT) assessed the efficacy of improving functional status and QoL (Table 5). The findings were mixed. Half of the studies reported, significant improvement in various domains of QoL in the intervention compared with the control groups: functioning,<sup>26,28,32</sup> general health,<sup>28</sup> physical, social,<sup>28,31</sup> environmental and mental health domains of QoL<sup>31</sup> and in the overall QoL.<sup>37</sup> In one study, there was significant improvement in all domains of QoL except the mental health domain in those receiving CBT compared with

**Table 4** Psychological intervention to improve adherence

| Authors   | Final analysis, <i>n</i><br>(intervention/control) | Measurement   | Follow-up duration after post-intervention (months) | Group   | Assessment time point, mean (s.d.)/<br>mean/% |                     | Test statistics, <i>P</i>                   | Measure of effect                                 |                                      |  |   |
|---|--|---|---|---------|---|---------------------|---|---|--------------------------------------|--|---|
|   |  |   |   |         | Baseline assessment                           | End-line assessment |   |   |                                      |  |   |
| Adherence to medications<br>Husain <i>et al</i> 2017<br>(Pakistan) <sup>37</sup>    | 16/11  | MMAS  | –   | I-PE    | 1.7 (1.7)                                     | 0.9 (1.4)           | <i>Z</i> = 2.37,<br><i>P</i> = 0.018        | AMD = –1.22 (95% CI –2.18<br>to 0.14), SES = 0.81 |                                      |  |   |
|   |  |   |   | TAU     | 1.3 (1.7)                                     | 2.1 (1.5)           |   |   |                                      |  |   |
| Rahmani <i>et al</i> 2016 (Iran) <sup>34</sup>                                      | 36/36  | MARS  | –   | G-PE    | 6.8 (1.9)                                     | 9.4 (2.4)           | <i>t</i> = 0.29,<br><i>P</i> < 0.001        | AMD = 2.3 (95% CI 2.21 to<br>2.14)                |                                      |  |   |
|   |  |   |   | TAU     | 6.6 (1.4)                                     | 7.1 (2.2)           |   |   |                                      |  |   |
|   |  |   |   | PE      | 10.6 (2.5)                                    | 17.8 (3.7)          |   |   |                                      |  |   |
|   |  | Total score, MAC  | –   | TAU     | 9.8 (2.2)                                     | 10.1 (2.3)          | <i>t</i> = 0.35,<br><i>P</i> < 0.001        | AMD = 7.7 (95% CI 7.20 to<br>9.50)                |                                      |  |   |
| Javadpour <i>et al</i> 2013 (Iran) <sup>31</sup>                                    | 45/41  | MARS  | 18  | I-PE    | –   | 7.91                | <i>P</i> = 0.008                            | –   |                                      |  |   |
|   |  |   |   | TAU     | –   | 3.73                |   |   |                                      |  |   |
| Bahredar <i>et al</i> 2014 (Iran) <sup>32</sup>                                     | 15/15/15   | MARS  | 6   | G-PE    | 6.27 (0.88)                                   | 7.92 (1.38)         | <i>F</i> (2,31) = 55.1,<br><i>P</i> < 0.001 | –   |                                      |  |   |
|   |  |   |   | TAU     | 6.53 (0.64)                                   | 4.33 (0.49)         |   |   |                                      |  |   |
| Bordbar <i>et al</i> 2009 (Iran) <sup>33</sup>                                      | 29/28  | Duration of continuing medication<br>in month             | 3   | Placebo | 6.47 (0.52)                                   | 4.36 (0.67)         | <i>t</i> = 1.23,<br><i>P</i> = 0.227        | –   |                                      |  |   |
|   |  |   |   | G-FPE   | –   | 2.46 (0.46)         |   |   |                                      |  |   |
|   |  |   |   | TAU     | –   | 2.67 (0.48)         |   |   |                                      |  |   |
|   |  |   |   | 6       | G-FPE   | –                   |   |   | 5.76 (0.51)                          | <i>t</i> = 4.36,<br><i>P</i> < 0.001       | – |
|   |  |   |   | TAU     | –   | 5.00 (0.77)         |   |   | <i>t</i> = 4.88,<br><i>P</i> < 0.001 | –  |   |
|   |  |   |   | 9       | G-FPE   | –                   |   |   | 8.48 (0.95)                          | <i>t</i> = 7.04 (1.26)<br><i>P</i> < 0.001 | – |
|   |  |   | 12  | G-FPE   | –   | 11.41 (1.02)        | <i>t</i> = 6.88,<br><i>P</i> < 0.001        | –   |                                      |  |   |
|   |  |   |   | TAU     | –   | 9.14 (1.43)         | <i>P</i> = 0.008                            | –   |                                      |  |   |
| Dogan & Sabanciogullari<br>2003 (Turkey) <sup>28</sup>                              | 14/12  | Proportion of patients who use<br>lithium regularly       | –   | I-PE    | 35.7%   | 85.7%               | <i>P</i> = 0.016                            | –   |                                      |  |   |
|   |  |   |   | TAU     | 50%   | 41.7%               |   |   |                                      |  |   |
|   |  | Proportion of patients with normal<br>serum lithium level | –   | I-PE    | 57.1%   | 100%                |   | –   |                                      |  |   |
|   |  |   | –   | TAU     | 58.3%   | 58.3%               |   | –   |                                      |  |   |
| Eker & Harkin 2012<br>(Turkey) <sup>29</sup>  | 30/33  | MARS  | –   | G-PE    | 40%   | 86.7%               | $\chi^2 = 24.649$ ,<br><i>P</i> < 0.01      | –   |                                      |  |   |
|   |  |   | –   | TAU     | 38.9%   | 24.2%               |   | –   |                                      |  |   |
| George <i>et al</i> 2013 (India) <sup>35</sup>                                      | 24/26  | Patient's diary and counting<br>tablets                   | 3   | G-PE    | –   | 100%                | <i>P</i> = 0.111                            | –   |                                      |  |   |
|   |  |   | –   | TAU     | –   | 84.6%               |   | –   |                                      |  |   |
| Adherence to psychiatric<br>visit<br>Bordbar <i>et al</i> 2009 (Iran) <sup>33</sup> | 29/28  | Number of psychiatric visit                               | 3   | G-FPE   | –   | 2.76 (0.43)         | <i>t</i> = 1.38,<br><i>P</i> < 0.017        | –   |                                      |  |   |
|   |  |   |   | TAU     | –   | 2.57 (0.57)         |   |   |                                      |  |   |
|   |  |   |   | 6       | G-FPE   | –                   |   |   | 5.34 (0.81)                          | <i>t</i> = 3.72,<br><i>P</i> < 0.001       | – |
|   |  |   |   | –       | TAU   | –                   |   |   | 4.46 (0.96)                          | <i>t</i> = 3.98,<br><i>P</i> < 0.001       | – |
|   |  |   |   | 9       | G-FPE   | –                   |   |   | 7.72 (1.36)                          | <i>t</i> = 5.52,<br><i>P</i> < 0.001       | – |
|   |  |   |   | –       | TAU   | –                   |   |   | 6.21 (1.50)                          | <i>t</i> = 7.86 (1.84)<br><i>P</i> < 0.001 | – |
|   |  |   | 12  | G-FPE   | –   | 10.34 (1.54)        | <i>t</i> = 5.52,<br><i>P</i> < 0.001        | –   |                                      |  |   |
|   |  |   | –   | TAU     | –   | 7.86 (1.84)         | <i>P</i> = 0.02                             | –   |                                      |  |   |
| Faridhosseini <i>et al</i> 2017<br>(Iran) <sup>30</sup>                             | 12/12  | Patient and family report                                 | 6   | G-PE    | –   | 3.25 (0.69)         | <i>P</i> = 0.02                             | –   |                                      |  |   |
|   |  |   | –   | TAU     | –   | 1.41 (1.67)         |   | –   |                                      |  |   |

MMAS, Morisky Medication Adherence Scale; I-PE, individual psychoeducation; TAU, treatment as usual; AMD, adjusted mean difference; SES, standardised effect size; MARS, Medication Adherence Rating Scale; G-PE, group psychoeducation; MAC, Medicine Adherence Checklist; PE, psychoeducation; G-FPE, group family psychoeducation.

**Table 5** Psychological intervention to improve quality of life and functioning

| Reference  | Final analysis, <i>n</i> (intervention/control)  | Intervention            | Follow-up duration after post-intervention (month) | Outcome                                     | Test statistics and <i>P</i> | Measure of effect                            |
|--|--|-------------------------|--|---|------------------------------|--|
| Husain <i>et al</i> 2017 (Pakistan) <sup>37</sup>    | 16/11  | I-PE v. TAU             | 3  | Overall QoL in EQ-5D index                  | $Z = 2.47, P = 0.01$         | AMD = 0.24 (95% CI 0.1–0.5),<br>SES = 0.88   |
|  |  |                         |  | Overall QoL in EQ-5D VAS                    | $Z = 3.65, P < 0.001$        | AMD = 26.8 (95% CI 12.2–41.8),<br>SES = 1.14 |
| Dogan & Sabanciogullari 2003 (Turkey) <sup>28</sup>  | 14/12  | I-PE v. TAU             | 3  | General health domain                       | $Z = 2.56, P < 0.01^a$       |  |
|  |  |                         |  | Physical aspect                             | $Z = 2.67, P < 0.01^a$       |  |
|  |  |                         |  | Psychological                               | $Z = 1.58, P > 0.05^a$       |  |
|  |  |                         |  | Social aspects                              | $Z = 2.10, P < 0.05^a$       |  |
| Javadpour <i>et al</i> 2013 (Iran) <sup>31</sup>     | 45/41  | I-PE v. TAU             | 18   | Environmental                               | $Z = 1.38, P > 0.05^a$       |  |
|  |  |                         |  | Physical aspect                             | $P < 0.001$                  |  |
|  |  |                         |  | Mental health                               | $P < 0.001$                  |  |
|  |  |                         |  | Social aspects                              | $P < 0.001$                  |  |
| Faridhosseini <i>et al</i> 2017 (Iran) <sup>30</sup> | 12/12  | G-PE v. TAU             | –  | Overall QoL                                 | $P = 0.196$                  | Mean 3.12 (s.d. = 2.34)                      |
|  | Cuhadar <i>et al</i> 2014 (Turkey) <sup>27</sup> | 24/23                   | G-PE v. TAU  | –   | Emotional functioning        |  |
|  |  |                         |  | Mental functioning                          | $Z = -1.93, P = 0.05^a$      |  |
|  |  |                         |  | Sexual functioning                          | $Z = -0.34, P = 0.73^a$      |  |
|  |  |                         |  | Feelings of stigmatisation                  | $Z = -0.95, P = 0.34^a$      |  |
|  |  |                         |  | Introversion                                | $Z = -1.50, P = 0.13^a$      |  |
|  |  |                         |  | Domestic relationships                      | $Z = -2.18, P = 0.03^a$      |  |
|  |  |                         |  | Relations with friends                      | $Z = -1.59, P = 0.11^a$      |  |
|  |  |                         |  | Participating in social activities          | $Z = -1.80, P = 0.07^a$      |  |
|  |  |                         |  | Daily and recreational activities           | $Z = -0.15; P = 0.88^a$      |  |
|  |  |                         |  | Taking initiative and using one's potential | $Z = -0.00, P = 1.00^a$      |  |
|  |  |                         |  | Work  | $Z = -0.54, P = 0.59^a$      |  |
|  |  |                         |  | Emotional functioning                       | $t = 4.04, P < 0.001$        |  |
|  |  |                         |  | Intellectual functioning                    | $t = 7.46, P < 0.001$        |  |
|  |  |                         |  | Sexual functioning                          | $t = 1.87, P > 0.050$        |  |
|  |  |                         |  | Feelings of stigmatisation                  | $t = 7.84, P < 0.001$        |  |
| Social withdrawal                                    | $t = 7.00, P < 0.001$                            |                         |  |   |                              |  |
| Household relations                                  | $t = 7.84, P < 0.001$                            |                         |  |   |                              |  |
| Relations with friends                               | $t = 3.46, P < 0.001$                            |                         |  |   |                              |  |
| Participating in social activities                   | $t = 3.66, P < 0.001$                            |                         |  |   |                              |  |
| Daily and recreational activities                    | $t = 3.11, P < 0.005$                            |                         |  |   |                              |  |
| Taking initiative and self-sufficiency               | $t = 3.61, P < 0.001$                            |                         |  |   |                              |  |
| Bahredar <i>et al</i> 2014 (Iran) <sup>32</sup>      | 15/15/15   | G-PE v. placebo and TAU | 6  | Occupation                                  | $t = 2.01, P < 0.050$        |  |
|  |  |                         |  | GAF score                                   | $F(2,31) = 90.93, P < 0.001$ |  |

(Continued)



**Table 5** (Continued)

| Reference  | Final analysis, <i>n</i> (intervention/control) | Intervention    | Follow-up duration after post-intervention (month) | Outcome                             | Test statistics and <i>P</i> | Measure of effect |
|--|---|-----------------|--|-------------------------------------|------------------------------|-------------------|
| Cardoso 2014 (Brazil) <sup>21</sup>                | 19/26   | G-PE v. TAU     | 6  | Functional capacity                 | $F = 0.08, P = 0.78$         |                   |
|  |   |                 |  | Pain                                | $F = 1.98, P = 0.17$         |                   |
|  |   |                 |  | General health status               | $F = 0.04, P = 0.84$         |                   |
|  |   |                 |  | Vitality                            | $F = 0.39, P = 0.54$         |                   |
|  |   |                 |  | Social aspects                      | $F = 0.62, P = 0.44$         |                   |
|  |   |                 |  | Emotional aspects                   | $F = 0.24, P = 0.63$         |                   |
| de Barros <i>et al</i> 2012 (Brazil) <sup>22</sup> | 28/18   | G-PE v. placebo | 12   | Mental health                       | $F = 1.19, P = 0.28$         |                   |
|  |   |                 |  | Social domain                       | $P = 0.42$                   | ES = 0.42         |
|  |   |                 |  | Environmental domain                | $P = 0.82$                   |                   |
|  |   |                 |  | Functioning                         | $P = 0.59$                   | ES = 0.03         |
|  |   |                 |  | Clinical improvement patient view   | $P = 0.02$                   | ES = 0.35         |
|  |   |                 |  | Clinical improvement clinician view | $P = 0.57$                   | ES = 0.04         |
| Costa <i>et al</i> 2012 (Brazil) <sup>23</sup>     | 25/12   | G-CBT v. TAU    | 6  | Functional capacity                 | $P = 0.007$                  | $R^2 = 0.65$      |
|  |   |                 |  | Pain                                | $P = 0.020$                  | $R^2 = 0.60$      |
|  |   |                 |  | General health status               | $P = 0.002$                  | $R^2 = 0.77$      |
|  |   |                 |  | Vitality                            | $P = 0.036$                  | $R^2 = 0.46$      |
|  |   |                 |  | Social aspects                      | $P = 0.044$                  | $R^2 = 0.41$      |
|  |   |                 |  | Emotional aspects                   | $P = 0.001$                  | $R^2 = 0.56$      |
|  |   |                 |  | Mental health                       | $P = 0.081$                  | $R^2 = 0.46$      |

I-PE, individual psychoeducation; TAU, treatment as usual; AMD, adjusted mean difference; SES, standardised effect size; VAS, visual analogue scale; G-PE, group psychoeducation; QoL, quality of life; GAF, Global Assessment of Functioning; ES, effect size; G-CBT, group cognitive-behavioural therapy;  $R^2$ , squared value of correlation coefficient or the proportion of explained variation.  
a. The comparison was made within arm and the reported result for the treatment group.

treatment as usual.<sup>23</sup> The rest of the studies did not reported significant differences between groups.<sup>21,22,27,30</sup>

## Discussion

This is the first systematic review synthesising the full range of psychological intervention studies that have been conducted among people with bipolar disorder in LMICs. In all studies reviewed, psychological interventions were given as adjuncts to treatment as usual, although the treatment as usual may have varied depending on drug licensing and treatment guidelines in each country. Nearly all of the included studies were conducted in upper-middle-income countries and none of the studies were from low-income countries compromising ability for direct generalisation of findings to low-income country settings. Absence of such studies in low-income countries may be linked to the broader lack of attention to bipolar disorder globally as well as in LMICs. The scarcity of clinician researchers<sup>38</sup> coupled with the poor funding environment may explain the scarcity of data on psychopathology, incidence, prevalence and course of bipolar disorder in LMICs.<sup>39</sup> However, even if focusing on upper-middle-income countries, these studies are important bridges to the broader LMIC setting than studies conducted in high-income countries. Additionally, the core principles of treatment were shared among the studies. For example, psychoeducation included in all the studies, is naturally consistent across settings. Most of the studies were tested in teaching or public hospitals with no intervention adaptations to the local context, which adds to the challenge of transferring these interventions. Nonetheless, identifying interventions of proven efficacy that have at least been tested outside of a high-income setting is a good starting point for adapting psychological intervention for LMICs. Therefore, they can be considered as potential candidates for further adaptation. Such an approach was taken when adapting psychological interventions for perinatal common mental disorders in LMICs with some success.<sup>40</sup> In general, the findings suggest the need for rigorous studies in LMICs.

Overall, the reviewed studies demonstrate the efficacy of adjunctive psychological interventions for bipolar disorder in terms of improving both depressive and manic symptoms, reducing relapse, hospital admissions and internalised stigma, improving QoL, treatment adherence and knowledge and attitudes about bipolar disorder

The majority of the studies assessed the efficacy of psychoeducation and all studies included a psychoeducation component. This is in line with the World Health Organization mhGAP intervention guideline, which endorses routine psychoeducation for people with bipolar disorders.<sup>15</sup> However, the mhGAP does not provide guidance on the number of sessions, content and delivery of the psychoeducation. In this review, 3 to 12 sessions of group, individual and family psychoeducation were effective in reducing relapse, hospital admissions and illness severity for both depression and mania. Therefore, a minimum of three sessions of psychoeducation may be required although a lower number of sessions may have to be tested. Furthermore, the mhGAP guideline is designed to be used by general health workers. However, in this review, most psychological interventions were delivered by mental health specialists and there was no evidence in relation to task-sharing with general health workers. This implies that there is no evidence to support psychoeducation provided by general health workers and calls for further evidence on this from LMICs.

It was also of interest to note that just one session of family psychoeducation improved outcomes on multiple domains: treatment adherence, relapse rates and hospital admissions.<sup>33</sup> Given the family orientation of care in LMICs, brief family psychoeducation

is a promising intervention that could be tested in the general healthcare context. Although this review confirms the benefits of psychological interventions as reported in high-income countries,<sup>41,42</sup> caution may be required in patients with a long duration of illness and multiple relapses. One of the reports where most of the participants had experienced multiple relapses and a long duration of illness (an average of 19 years), depressive symptoms worsened in both the treatment and control groups.<sup>22</sup> This may indicate that psychological interventions may be more effective for people with bipolar disorder who have experienced fewer relapses and have a short disease duration.<sup>12,42</sup> Findings related to CBT were consistent with those from high-income countries.<sup>41,42</sup>

## Limitations

The review was comprehensive in terms of databases searched and types of psychological interventions and study designs. However, a meta-analysis was not possible because of the heterogeneity of the included studies in terms of the type of interventions, number of sessions and duration of follow-up time and format of intervention delivery. Second, studies with negative findings might not have been published. Additionally, two of the papers<sup>27,28</sup> carried out within-group comparisons with post-assessment against baseline. Non-availability of the raw data precluded re-analysis. Third, since nearly all the studies were from upper-middle-income countries, the findings may not be directly generalisable to low-income country settings (see supplementary file 7 for a list of countries by income group).

## Implications

The reviewed literature showed promising results relating to the efficacy of adjunctive psychological interventions on a broad range of clinical and QoL parameters in LMICs. However, virtually all studies identified in this comprehensive review were from upper-middle-income countries and none involved general health workers. Contextually appropriate adaptation of interventions for low-income settings and for task-shifted care as well as larger-scale studies are important next steps.

**Mekdes Demissie**, BSc, MSc, Lecturer, College of Health Sciences, Department of Psychiatry, Addis Ababa University, Ethiopia; **Charlotte Hanlon**, BMBS, MSc, MRCPsych, PhD, Associate Professor, College of Health Sciences, Department of Psychiatry, Addis Ababa University, Ethiopia and Centre for Global Mental Health, Institute of Psychiatry, Psychology and Neuroscience, Health Services and Population Research, King's College London, UK; **Rahel Birhane**, BSc, MSc, Research Assistant, College of Health Sciences, Department of Psychiatry, Addis Ababa University, Ethiopia; **Lauren Ng**, BA, MA, PhD, Assistant Professor, School of Medicine, Boston University, USA; **Girmay Medhin**, BSc, MSc, PhD, Associate Professor, Akililu Lemma Institute of Pathobiology, Addis Ababa University, Ethiopia; **Abebaw Fekadu**, MD, MSc, MRCPsych, PhD, Associate Professor, College of Health Sciences, Department of Psychiatry and Centre for Innovative Drug Development and Therapeutic Studies for Africa (CDT-Africa), Collage of Health Science, Addis Ababa University, Ethiopia and Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex and Center for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, King's College London, UK

**Correspondence:** Mekdes Demissie, College of Health Sciences, Department of Psychiatry, Addis Ababa University, PO BOX 9086, Addis Ababa, Ethiopia.  
Email: [smekdem@yahoo.com](mailto:smekdem@yahoo.com)

First received 19 Mar 2018, final revision 9 Jul 2018, accepted 10 Jul 2018

## Funding

This work is supported through the DELTAS Africa Initiative (DEL-15-01) and Addis Ababa University. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (DEL-15-01) and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.

A.F. is supported by the Medical Research Council/Department for International Development through the African Research Leader scheme.

## Supplementary material

Supplementary material is available online at <https://doi.org/10.1192/bjo.2018.46>.

## References

- World Health Organization. *mhGAP: Mental Health Gap Action Programme: Scaling Up Care for Mental, Neurological and Substance Use Disorders*. WHO, 2008.
- Fekadu A, Medhin G, Kebede D, Alem A, Cleare AJ, Prince M, et al. Excess mortality in severe mental illness: 10-year population-based cohort study in rural Ethiopia. *Br J Psychiatry* 2015; **206**: 289–96.
- Fekadu A, Kebede D, Alem A, Fekadu D, Mogga S, Negash A, et al. Clinical outcome in bipolar disorder in a community-based follow-up study in Butajira, Ethiopia. *Acta Psychiatr Scand* 2006; **114**: 426–34.
- Fekadu A, Hanlon C, Thornicroft G, Lund C, Kaaya S, Alem A, et al. Care for bipolar disorder in LMICs needs evidence from local settings. *Lancet Psychiatry* 2015; **2**: 772–3.
- Kebede D, Alem A, Shibire T, Deyessa N, Negash A, Beyero T, et al. Symptomatic and functional outcome of bipolar disorder in Butajira, Ethiopia. *J Affect Disord* 2006; **90**: 239–49.
- Negash A, Kebede D, Alem A, Melaku Z, Deyessa N, Shibire T, et al. Neurological soft signs in bipolar I disorder patients. *J Affect Disord* 2004; **80**: 221–30.
- Keck Jr PE, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. *Am J Psychiatry* 1998; **1**: 44–52.
- National Collaborating Centre for Mental Health. *Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. NICE Clinical Guideline CG38*. British Psychological Society and The Royal College of Psychiatrists. 2006.
- World Health Organization. *Department of Mental Health, Substance Abuse. Mental Health Atlas 2005*. WHO, 2005.
- World Health Organization. *Update of the Mental Health Gap Action Programme (mhGAP) Guidelines for Mental, Neurological and Substance Use Disorders, 2015*. WHO, 2015.
- Pakpoor J, Agius M. A review of the adverse side effects associated with antipsychotics as related to their efficacy. *Psychiatr Danub* 2014; **26**: 273–84.
- Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. *Br J Psychiatry* 2006; **188**: 313–20.
- Zaretsky A, Lancee W, Miller C, Harris A, Parikh SV. Is cognitive-behavioural therapy more effective than psychoeducation in bipolar disorder? *Can J Psychiatry* 2008; **53**: 441–8.
- Perlick DA, Miklowitz DJ, Lopez N, Chou J, Kalvin C, Adzhiashvili V, et al. Family-focused treatment for caregivers of patients with bipolar disorder. *Bipolar Disord* 2010; **12**: 627–37.
- Dua T, Barbui C, Clark N, Fleischmann A, Poznyak V, van Ommeren M, et al. Evidence-based guidelines for mental, neurological, and substance use disorders in low-and middle-income countries: summary of WHO recommendations. *PLoS Med* 2011; **8**: e1001122.
- PROSPERO. *Psychosocial Interventions for Bipolar Disorder in Low and Middle Income Countries: Systematic Review*. PROSPERO, no date ([http://www.crd.york.ac.uk/PROSPERO/display\\_record.php?ID=CRD42017054572](http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017054572)).
- World Bank. *World Bank Country and Lending Groups*. World Bank, no date (<https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>).
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMC Med* 2010; **8**: 18.
- Higgins JP, Green S. *Cochrane Handbook for Systematic Reviews of Interventions*. Wiley Online Library, 2008.
- Faria AD, de Mattos Souza LD, de Azevedo Cardoso T, Pinheiro KAT, Pinheiro RT, da Silva RA, et al. The influence of psychoeducation on regulating biological rhythm in a sample of patients with bipolar II disorder: a randomized clinical trial. *Psychol Res Behav Manage* 2014; **7**: 167.
- Cardoso TDA, Farias CDA, Mondin TC, da Silva GDG, Souza LDDM, da Silva RA, et al. Brief psychoeducation for bipolar disorder: impact on quality of life in young adults in a 6-month follow-up of a randomized controlled trial. *Psychiatry Res* 2014; **220**: 896–902.
- de Barros Pellegrinelli K, de O, Silval K, Dias V, Roso M, Bandeira M, et al. Efficacy of psychoeducation on symptomatic and functional recovery in bipolar disorder. *Acta Psychiatr Scand* 2013; **127**: 153–8.
- Costa R, Cheniaux E, Range B, Versiani M, Nardi A. Group cognitive behavior therapy for bipolar disorder can improve the quality of life. *Braz J Med Biol Res* 2012; **45**: 862–8.
- Gomes BC, Abreu LN, Brietzke E, Caetano SC, Kleinman A, Nery FG, et al. A randomized controlled trial of cognitive behavioral group therapy for bipolar disorder. *Psychother Psychosom* 2011; **80**: 144–50.
- Gumus F, Buzlu S, Cakir S. Effectiveness of individual psychoeducation on recurrence in bipolar disorder; a controlled study. *Arch Psychiatr Nurs* 2015; **29**: 174–9.
- Kurdal E, Tanriverdi D, Savas HA. The effect of psychoeducation on the functioning level of patients with bipolar disorder. *West J Nurs Res* 2014; **36**: 312–28.
- Cuhadar D, Cam M. Effectiveness of psychoeducation in reducing internalized stigmatization in patients with bipolar disorder. *Arch Psychiatr Nurs* 2014; **28**: 62–6.
- Dogan S, Sabanciogullari S. The effects of patient education in lithium therapy on quality of life and compliance. *Arch Psychiatr Nurs* 2003; **17**: 270–5.
- Eker F, Harkin S. Effectiveness of six-week psychoeducation program on adherence of patients with bipolar affective disorder. *J Affect Disord* 2012; **138**: 409–16.
- Faridhosseini F, Baniyasi M, Fayyazi Bordbar MR, Pourgholami M, Ahrari S, Asgharipour N. Effectiveness of psychoeducational group training on quality of life and recurrence of patients with bipolar disorder. *Iran J Psychiatry* 2017; **12**: 21–8.
- Javadpour A, Hedayati A, Dehbozorgi G-R, Azizi A. The impact of a simple individual psycho-education program on quality of life, rate of relapse and medication adherence in bipolar disorder patients. *Asian J Psychiatry* 2013; **6**: 208–13.
- Bahredar MJ, Farid AAA, Ghanizadeh A, Birashk B. The efficacy of psycho-educational group program on medication adherence and global functioning of patients with bipolar disorder type I. *Int J Commun Based Nurs Midwifery* 2014; **2**: 12.
- Bordbar MRF, Soltanifar A, Talaei A. Short-term family-focused psycho-educational program for bipolar mood disorder in Mashhad. *Iran J Med Sci* 2009; **34**: 104–9.
- Rahmani F, Ebrahimi H, Ranjbar F, Razavi SS, Asghari E. The effect of group psychoeducation program on medication adherence in patients with bipolar mood disorders: a randomized controlled Trial. *J Caring Sci* 2016; **5**: 287–97.
- George LS, Sharma P, Nair S. Effect of psycho-educative intervention on adherence to treatment, knowledge and attitude among persons with bipolar affective disorder (BPAD)—randomized controlled trial. *J Nurs Health Sci* 2013; **1**: 12–7.
- Ives-Deliperi VL, Howells F, Stein DJ, Meintjes EM, Horn N. The effects of mindfulness-based cognitive therapy in patients with bipolar disorder: a controlled functional MRI investigation. *J Affect Disord* 2013; **150**: 1152–7.
- Husain MI, Chaudhry IB, Rahman RR, Hamirani MM, Mehmood N, Haddad PM, et al. Pilot study of a culturally adapted psychoeducation (CaPE) intervention for bipolar disorder in Pakistan. *Int J Bipolar Disord* 2017; 11 Feb (Epub ahead of print).
- Hanlon C. Next steps for meeting the needs of people with severe mental illness in low-and middle-income countries. *Epidemiol Psychiatr Sci* 2017; **26**: 348–54.
- Fekadu A, Hanlon C, Thornicroft G, Lund C, Kaaya S, Alem A, et al. Care for bipolar disorder in LMICs needs evidence from local settings. *Lancet Psychiatry* 2015; **2**: 772–3.
- Clarke K, King M, Prost A. Psychosocial interventions for perinatal common mental disorders delivered by providers who are not mental health specialists in low-and middle-income countries: a systematic review and meta-analysis. *PLoS Med* 2013; **10**: e1001541.
- Miziou S, Tsiatsipa E, Moysidou S, Karavelas V, Dimelis D, Polyzoidou V, et al. Psychosocial treatment and interventions for bipolar disorder: a systematic review. *Ann Gen Psychiatry* 2015; **14**: 19.
- Reinares M, Sánchez-Moreno J, Fountoulakis KN. Psychosocial interventions in bipolar disorder: what, for whom, and when. *J Affect Disord* 2014; **156**: 46–55.

